Afamelanotide mastery course
Unit 10 of 12
How the implant is administered
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, every two months,…
The approved protocol, and what gray-market use is not
Afamelanotide is given as a 16 mg controlled-release implant placed under the skin by a clinician, every two months, and in September 2025 the EMA removed the European label's recommended maximum of four implants a year. This unit explains that approved protocol and the pharmacokinetic logic behind it.
It then clearly separates the gray market, where unlicensed injectable products are sold online, as something described, not endorsed. This is education only, not a protocol, and afamelanotide is clinician-administered by design.